导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.09% | 923/4773 |
| 近一周 | -2.22% | 1525/5462 |
| 近一月 | -4.81% | 2778/5421 |
| 近一季 | -4.41% | 1626/5209 |
| 近半年 | -1.57% | 1635/4920 |
| 近一年 | 13.46% | 780/4366 |
| 近两年 | 65.38% | 1068/2954 |
| 近三年 | 28.23% | 1123/2253 |
| 成立以来 | 23.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.41% 946/4961 |
15.15% 1704/5312 |
- - |
- - |
| 2025 | 28.77% 1452/4813 |
2.37% 1390/3635 |
2.27% 1695/4076 |
19.06% 2195/4524 |
3.30% 700/4813 |
| 2024 | -1.77% 2173/3463 |
-3.02% 1464/2808 |
-5.78% 1795/3014 |
10.64% 2608/3129 |
-2.84% 2190/3463 |
| 2023 | -7.68% 938/2656 |
8.12% 494/2280 |
-5.98% 1571/2385 |
-4.42% 1138/2515 |
-4.99% 1228/2655 |
| 2022 | -19.54% 863/2207 |
-13.85% 856/1919 |
2.74% 1263/2016 |
-13.06% 826/2113 |
4.57% 533/2208 |
| 2021 | 14.67% 324/1822 |
-1.70% 533/1255 |
8.91% 601/1330 |
4.82% 317/1466 |
2.19% 665/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 诺安中证500指数增强C VS. 长安沪深300非周期A(740101) |